Dr. Rolsma is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3601 21st Ave S
Nashville, TN 37232Phone+1 615-322-3000
Summary
- I am a clinician and researcher at Monroe Carell Jr. Children's Hospital at Vanderbilt. My clinical interests include both general and immunocompromised pediatric infectious diseases. My research focus is clinical research with specific interests in therapeutics and therapeutic drug monitoring, critically ill patients, and clinical trials.
Education & Training
Vanderbilt University Medical CenterFellowship, Pediatric Infectious Diseases, 2019 - 2022- Vanderbilt University Medical CenterResidency, Pediatrics, 2016 - 2019
Medical College of WisconsinClass of 2016, MD/PhD
Michigan State UniversityBS, Microbiology, with high honors, 2003 - 2007
Certifications & Licensure
TN State Medical License 2019 - 2027- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Infectious Diseases
- American Heart AssociationBLS
Awards, Honors, & Recognition
- David T. Karzon Fellowship in Pediatric Infectious Diseases Division of Pediatric Infectious Diseases, Vanderbilt University Medical Center, 2020-2021
- St. Jude/Pediatric Infectious Diseases Society Research Conference and Pediatric Transplant Symposium Resident Conference Attendance Scholarship St. Jude/Pediatric Infectious Diseases Society Research Conference and Pediatric Transplant Symposium, 2018
- Chrysalis Project participant American Academy of Allergy, Asthma, & Immunology, 2017
Clinical Trials
- A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 Start of enrollment: 2020 Jul 27
- A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Start of enrollment: 2020 Nov 12
- A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox Start of enrollment: 2023 Mar 22
- Join now to see all
Publications & Presentations
PubMed
- Utilizing an Opportunistic Clinical Study and Population-Based Pharmacokinetic Models to Identify Rational Empiric Dosing Regimens for Piperacillin-Tazobactam in Criti...Joshua A Reeder, C Buddy Creech, Roger L Nation, Kenan Gu, Demet Nalbant
Journal of Clinical Pharmacology. 2024-12-03 - Population Pharmacokinetic Modeling of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients with Cystic Fibrosis.Stephanie L Rolsma, Andrew Sokolow, Pratish C Patel, Katherine Sokolow, Natalia Jimenez-Truque
The Journal of Infectious Diseases. 2024-09-30 - Outcomes of Early Surgical Procedures for Children With Acute Hematogenous Osteomyelitis.Justin B Searns, Matt Hall, Meghan Birkholz, Brittany B Hubbell, Andrew S Kern-Goldberger
Pediatrics. 2024-07-01
Books/Book Chapters
Grant Support
- Childhood Infections Research Program T32 AwardNational Institute of Allergy and Infectious Diseases2020–2022
Research History
- Sub-investigatorVaccine and Treatment Evaluation Unit (VTEU), “A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.CoV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older.”2020 - 2021
- Sub-investigatorVaccine and Treatment Evaluation Unit (VTEU), “A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older.”2020 - 2021
Professional Memberships
- Infectious Disease Society of AmericaMember
- Pediatric Infectious Diseases SocietyMember
- American Society for Clinical PharmacologyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
